Product Pipeline
Pioneering An Innovative Strategy for Product Development
Functional Genetics has applied innovative technologies to improve the treatment of infectious diseases. The Company has one monoclonal antibody product (FGI-101-1A6) currently in the clinic undergoing human safety trials and two additional monoclonal antibody products (FGI-110 and FGI-111) in early stage development. All of FGI's products are based on the novel paradigm of host-oriented therapeutics to treat infectious disease.
